805 results on '"L. De Smet"'
Search Results
2. Skin grafting prevents recurrence in Dupuytren's disease and extension correlates with fibrosis diathesis score
- Author
-
I. Couck, Marieke Torrekens, Ilse Degreef, M. Van Nuffel, and L. De Smet
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Disease ,030230 surgery ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Disease severity ,Fibrosis ,Humans ,Medicine ,Orthopedics and Sports Medicine ,Family history ,Dupuytren's contracture ,030222 orthopedics ,integumentary system ,business.industry ,Rehabilitation ,Skin Transplantation ,Diathesis ,medicine.disease ,Surgery ,Dupuytren Contracture ,Skin grafting ,Disease Susceptibility ,Neoplasm Recurrence, Local ,medicine.symptom ,business ,Cohort study - Abstract
Full thickness grafting can be considered after fasciectomy for Dupuytren contracture in severe cases with skin shortage or in radical dermofasciectomy. It is a common dogma that these skin grafts may prevent disease recurrence. We reviewed 47 patients after fasciectomy and full-thickness skin grafting for Dupuytren contracture at 3-16 years' follow-up. Recurrence beneath the skin graft and extension of the disease in the rest of the hand were recorded. Age at onset, gender and factors considered to influence the outcome due to fibrosis diathesis, such as bilateral disease, family history and ectopic lesions, were noted. The Tubiana classification was used to grade disease severity at surgery and at follow-up. None of the patients manifested recurrence underneath the skin graft, but the disease did show extension in 83% of cases. Disease extension was more likely in patients with higher fibrosis diathesis scores. We conclude that skin grafting may prevent disease recurrence underneath the grafts, but extension of the disease correlates with fibrosis diathesis. LEVEL OF EVIDENCE: IV, therapeutic cohort study.
- Published
- 2021
3. Long-term follow-up of the three-ligament tenodesis for scapholunate ligament lesions: 9-year results
- Author
-
L. De Smet, N. van Beek, Ilse Degreef, Sofie Goeminne, and A. Borgers
- Subjects
Joint Instability ,medicine.medical_specialty ,Tenodesis ,030230 surgery ,Wrist ,03 medical and health sciences ,Grip strength ,0302 clinical medicine ,medicine ,Humans ,Orthopedics and Sports Medicine ,Lunate Bone ,Retrospective Studies ,030222 orthopedics ,business.industry ,Rehabilitation ,Retrospective cohort study ,Scapholunate ligament ,medicine.disease ,Surgery ,Complex regional pain syndrome ,medicine.anatomical_structure ,Ligaments, Articular ,Cohort ,Ligament ,Septic arthritis ,business ,Follow-Up Studies - Abstract
We report on a retrospective cohort of 50 cases of three-ligament tenodesis for scapholunate instability. Fifteen cases (30% of our cohort) needed salvage surgery (11 proximal row carpectomies, 2 partial and 2 total wrist fusions) at an average of 33 months and are considered “failures”. Of the 35 remaining cases (“success”), 16 (32% of our cohort) were reviewed at average 111 months and had good functional outcomes (QuickDASH 18/100, PRWE 11/100, pain 1/10, satisfaction 9/10). Return to work was 81% and grip strength was 80% of the opposite side. Radiological review found no significant correction in the short-term: scapholunate angle (SLA) from 72° to 69° (p = 0.544), scapholunate distance (SLD) from 3.4 mm to 3.4 mm (p = 0.833) and radiolunate angle (RLA) from 17° to 13° (p = 0.253). A significant deterioration in SLA from 72° to 80° (p = 0.014), not correlated to function, was seen at final follow-up. Radiographic progression to wrist degeneration was seen in 63% of successful cases. In failed cases, we noticed inferior radiographic parameters in the short-term: SLD of 4.6 mm in failed versus 3.4 mm in successful cases (p = 0.038) and RLA of 22° in failed versus 13° in successful cases (p = 0.046). Complication rate was 10% (2 scaphoid necroses, 1 septic arthritis and 2 complex regional pain syndromes). Despite radiological deterioration of SLA and development of degeneration in most cases, three-ligament tenodesis can give satisfactory wrist function in some patients, but we observed a significant number of failures and a high complication rate. Level of evidence IV
- Published
- 2021
4. Lateral elbow tendinopathy: surgery versus extracorporeal shock wave therapy
- Author
-
L. De Smet, Ilse Degreef, P. Brys, S. Defoort, and Koen Peers
- Subjects
Extracorporeal Shockwave Therapy ,medicine.medical_specialty ,Extracorporeal shock wave therapy ,medicine.medical_treatment ,Tendinosis ,030230 surgery ,Lithotripsy ,Elbow pain ,03 medical and health sciences ,0302 clinical medicine ,Elbow ,medicine ,Tennis elbow ,Humans ,Orthopedics and Sports Medicine ,Prospective Studies ,Prospective cohort study ,030222 orthopedics ,business.industry ,Rehabilitation ,Tennis Elbow ,medicine.disease ,Surgery ,Treatment Outcome ,Tendinopathy ,Kidney stones ,business - Abstract
Lateral elbow pain caused by tendinopathy – tendinosis – or tennis elbow is a highly prevalent problem. Unfortunately, no treatment method can guarantee clinical success. Inspired by the lithotripsy technique used for kidney stones, extracorporeal shock wave therapy (ESWT) has been introduced as an alternative to surgical treatment 25 years ago. In a randomized prospective study, we compared 15 patients with lateral elbow tendinopathy who were operated and 14 who underwent ESWT. Almost all patients had good or excellent outcomes according to the criteria by Verhaar. Subjective improvement was 57% for the ESWT group and 76% for the surgery group. No significant differences between both groups were found (p = 0.07). We therefore recommend considering non-invasive techniques such as ESWT treatment prior to surgery in tennis elbow.
- Published
- 2021
5. E-book: Dermatologie 2021
- Author
-
A.-S. De Vos, L. Temmerman, L. De Smet, L. De Laet, M. Schellen, M. Depypere, D. Martiny, M. Hallin, P. De Haes, E. Vanbelleghem, J. Werbrouck, S. Verstraete, L. Libbrecht, F. D’Heygere, A. Vanneste, M. Garmyn, M.-A. Morren, S. Desmedt, V. Desmedt, T. Billiet, C. George, W. Meersseman, and F. Castelijns
- Subjects
General Medicine - Published
- 2022
6. Een perioculaire vorm van necrobiosis lipoidica
- Author
-
L. Temmerman, L. De Smet, and A. De Vos
- Subjects
General Medicine - Abstract
A periocular form of necrobiosis lipoidica Necrobiosis lipoidica (NL) is an uncommon granulomatous skin disease of unknown origin. It is more often seen in patients with diabetes mellitus. Other cases describe an association with conditions like autoimmune thyroid disease, inflammatory bowel disease, sarcoidosis and rheumatoid arthritis. The skin lesions usually appear on the legs of the patient. Rarely, the disease presents in the face and/or scalp, in this case it is called “facial necrobiosis lipoidica” (FNL). When one or multiple annular, non-scaly plaques are observed in the face and/or scalp, it is important to think about FNL. The lesions are usually yellowish in the centre with areas of depigmentation and/or atrophy of the skin. In the periphery, the colour might be brown-red and sometimes an elevated border can be observed. FNL may look like another skin disease called “necrobiotic xanthogranuloma”. For this reason, histology is crucial for a correct diagnosis. It is important to exclude underlying diabetes mellitus. Necrobiotic xanthogranuloma is frequently associated with paraproteinemia. Therefore, this condition has to be ruled out by means of a blood analysis. There are no guidelines available for the treatment of FNL, but topical tacrolimus 0,1% might be an effective therapy for these patients.
- Published
- 2021
7. Beta-blocker effect on ST-segment
- Author
-
Elvin Kedhi, Vincent Roolvink, Marcel Gosselink, Borja Ibanez, Fernando Alfonso, Valentin Fuster, Gonzalo Pizarro, Sonja Postma, Agustín Albarrán, Niels van Royen, José Luis Zamorano, Arnoud W J van 't Hof, Renicus S Hermanides, Robin Nijveldt, Maarten A.H. van Leeuwen, Erik Lipsic, Javier Botas, Jan J. Piek, Saman Rasoul, Francisco Fernández-Avilés, Jan Henk Dambrink, Victoria Hernandez-Jaras, Bart J. G. L. de Smet, Jan Paul Ottervanger, Enrico Fabris, Alberto García-Lledó, Evelien Kolkman, Alonso Mateos-Rodríguez, Wouter Remkes, MUMC+: MA Med Staf Spec Cardiologie (9), Cardiologie, RS: Carim - H01 Clinical atrial fibrillation, Dutch Heart Foundation (Holanda), Medtronic, Dutch Heart Foundation, Medtronic Inc, Cardiology, ACS - Atherosclerosis & ischemic syndromes, and ACS - Microcirculation
- Subjects
Male ,medicine.medical_specialty ,medicine.drug_class ,medicine.medical_treatment ,Enfermedad cardiovascular ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,PERCUTANEOUS CORONARY INTERVENTION ,METOPROLOL ,Coronary Artery Disease ,Placebo ,STEMI ,ST-T changes ,Electrocardiography ,Bolus (medicine) ,Double-Blind Method ,Internal medicine ,Infarto del miocardio ,medicine ,Antagonistas adrenérgicos beta ,ST segment ,Humans ,REPERFUSION ,Myocardial infarction ,Beta blocker ,Metoprolol ,Medicamento ,coronary intervention (PCI) ,Dose-Response Relationship, Drug ,beta blockers ,business.industry ,ELEVATION MYOCARDIAL-INFARCTION ,Percutaneous coronary intervention ,Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16] ,Intervención coronaria percutánea ,Middle Aged ,medicine.disease ,Adrenergic beta-1 Receptor Antagonists ,Treatment Outcome ,SIZE ,Conventional PCI ,Cardiology ,ST Elevation Myocardial Infarction ,Female ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
ObjectiveThe effect of early intravenous (IV) beta-blockers (BBs) administration in patients undergoing primary percutaneous coronary intervention (pPCI) on ST-segment deviation is unknown. We undertook a prespecified secondary analysis of the Early Beta-blocker Administration before primary PCI in patients with ST-elevation Myocardial Infarction (EARLY-BAMI) trial to investigate the effect of early IV BB on ST-segment deviation.MethodsThe EARLY-BAMI trial randomised patients with ST-elevation myocardial infarction (STEMI) to IV metoprolol (2×5 mg bolus) or matched placebo before pPCI. The prespecified outcome, evaluated by an independent core laboratory blinded to study treatment, was the residual ST-segment deviation 1 hour after pPCI (ie, the percentage of patients with >3 mm cumulative ST deviation at 1 hour after pPCI).ResultsAn ECG for the evaluation of residual ST-segment deviation 1 hour after pPCI was available in 442 out of 683 randomised patients. The BB group had a lower heart rate after pPCI compared with placebo (71.2±13.2 vs 74.3±13.6, p=0.016); however, no differences were noted in the percentages of patients with >3 mm cumulative ST deviation at 1 hour after pPCI (58.6% vs 54.1%, p=0.38, in BB vs placebo, respectively) neither a significant difference was found for the percentages of patients in each of the four prespecified groups (normalised ST-segment; 1–3 mm; 4–6 mm;>6 mm residual ST-deviation).ConclusionsIn patients with STEMI, who were being transported for primary PCI, early IV BB administration did not significantly affect ST-segment deviation after pPCI compared with placebo. The neutral result of early IV BB administration on an early marker of pharmacological effect is consistent with the absence of subsequent improvement of clinical outcomes.
- Published
- 2020
8. Unbiased random mutagenesis contributes to a better understanding of the virulent behaviour ofPaenibacillus larvae
- Author
-
Dirk C. de Graaf, P. De Vos, Tine Descamps, and L. De Smet
- Subjects
0301 basic medicine ,American foulbrood ,Genotype ,Virulence Factors ,030106 microbiology ,Mutagenesis (molecular biology technique) ,Virulence ,medicine.disease_cause ,Applied Microbiology and Biotechnology ,Microbiology ,03 medical and health sciences ,medicine ,Animals ,Pathogen ,biology ,Pseudomonas aeruginosa ,Host (biology) ,Paenibacillus larvae ,General Medicine ,Bees ,biology.organism_classification ,United States ,Mutagenesis ,Larva ,Bacteria ,Biotechnology - Abstract
Aims: American foulbrood, caused by the Gram-positive bacteria Paenibacillus larvae, is one of the most severe bacterial diseases of the European honey bee. The bacterium has been known for long, but only the last decade the mechanisms used by the pathogen to cause disease in its host are starting to unravel. In this study, the knowledge of this virulent behaviour is expanded and several possible virulence factors are suggested. Methods and Results: Identification of possible virulence factors has been done by random mutagenesis to ensure an unbiased approach. A library of mutants was tested for a significant difference in virulence using in vitro exposure assays. Affected loci were characterized and their potential to contribute in virulence of the pathogen was assessed. Conclusions: The identified mutated loci dacB, dnaK, metN, ywqD, lysC, serC and gbpA are known to encode for virulence factors in other bacteria and are suggested to play a similar role in P. larvae. Significance and Impact of the Study: The study identified new possible virulence factors for P. larvae genotype ERIC I in an unbiased way. This contributes to the knowledge and understanding of the possible mechanisms used by this pathogen to colonize and kill its host.
- Published
- 2017
9. Recommendations for the use of bioresorbable vascular scaffolds in percutaneous coronary interventions : 2017 revision
- Author
-
Roberto Diletti, P. van der Harst, Bert Everaert, José P.S. Henriques, R J van der Schaaf, P. den Heijer, Sjoerd H. Hofma, Joanna J. Wykrzykowska, Jan C.A. Hoorntje, R.J. Van Geuns, Paul Smits, Auke P.J.D. Weevers, B. J. G. L. de Smet, and Jacques J. Koolen
- Subjects
medicine.medical_specialty ,Percutaneous ,Current generation ,medicine.medical_treatment ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,Psychological intervention ,030204 cardiovascular system & hematology ,Percutaneous coronary intervention ,Outcome monitoring ,03 medical and health sciences ,0302 clinical medicine ,medicine ,030212 general & internal medicine ,Myocardial infarction ,Intensive care medicine ,Prospective cohort study ,Everolimus ,business.industry ,medicine.disease ,Bioresorbable vascular scaffold ,Original Article ,Radiology ,Cardiology and Cardiovascular Medicine ,business ,Absorb BVS ,medicine.drug - Abstract
Contains fulltext : 182904.pdf (Publisher’s version ) (Open Access) BACKGROUND: To eliminate some of the potential late limitations of permanent metallic stents, the bioresorbable coronary stents or 'bioresorbable vascular scaffolds' (BVS) have been developed. METHODS: We reviewed all currently available clinical data on BVS implantation. RESULTS: Since the 2015 position statement on the appropriateness of BVS in percutaneous coronary interventions, several large randomised trials have been presented. These have demonstrated that achieving adequate 1 and 2 year outcomes with these first-generation BVS is not straightforward. These first adequately powered studies in non-complex lesions showed worse results if standard implantation techniques were used for these relatively thick scaffolds. Post-hoc analyses hypothesise that outcomes similar to current drug-eluting stents are still possible if aggressive lesion preparation, adequate sizing and high-pressure postdilatation are implemented rigorously. As long as this has not been confirmed in prospective studies the usage should be restricted to experienced centres with continuous outcome monitoring. For more complex lesions, results are even more disappointing and usage should be discouraged. When developed, newer generation scaffolds with thinner struts or faster resorption rates are expected to improve outcomes. In the meantime prolonged dual antiplatelet therapy (DAPT, beyond one year) is recommended in an individualised approach for patients treated with current generation BVS. CONCLUSION: The new 2017 recommendations downgrade and limit the use of the current BVS to experienced centres within dedicated registries using the updated implantation protocol and advise the prolonged usage of DAPT. In line with these recommendations the manufacturer does not supply devices to the hospitals without such registries in place.
- Published
- 2017
10. Investigating ultrasonic wave dispersion and attenuation in fresh cementitious materials: A combined numerical, analytical, and experimental approach
- Author
-
L. De Smet, Dimitrios G. Aggelis, Sokratis Iliopoulos, Faculty of Engineering, and Mechanics of Materials and Constructions
- Subjects
Materials science ,Scattering ,Wave propagation ,Attenuation ,Mechanical Engineering ,0211 other engineering and technologies ,02 engineering and technology ,Mechanics ,Microstructure ,Condensed Matter Physics ,01 natural sciences ,Characterization (materials science) ,Materials Science(all) ,021105 building & construction ,0103 physical sciences ,General Materials Science ,Ultrasonic sensor ,Cementitious ,Dispersion (water waves) ,010301 acoustics - Abstract
The heterogeneity of cement-based materials and the severe wave-microstructure interactions at the fresh state render the thorough investigation of ultrasonic wave propagation imperative, especially when the latter is used for material characterization and quality control. In this study, parallel to the advanced ultrasonic wave dispersion and attenuation experiments, numerical simulations are also performed offering faster, reliable and accurate solutions at low cost, as well as flexibility on the design and measured properties. Cement pastes and mortars are investigated and the observed dispersive and attenuative trends are further explained with scattering theories reinforcing the characterization potential. The results pinpoint air bubbles and sand grains as causes of the dispersion and attenuation frequency dependent trends. The distinct frequency regimes where these phenomena are observed allow for the more accurate characterization of the microstructure. For the first time, the strong qualitative and quantitative agreement between experiments, scattering theories, and numerical simulations provides holistic insights into wave propagation in fresh cementitious materials and firmly connects the dispersion and attenuation of waves to their origin.
- Published
- 2018
11. Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention
- Author
-
Niels van Royen, Sonja Postma, Elvin Kedhi, Gonzalo Pizarro, Victoria Hernandez-Jaras, Robin Nijveldt, Vincent Roolvink, Maarten A.H. van Leeuwen, Marcel Gosselink, Joaquín Alonso, Felipe Navarro, Borja Ibanez, Jan J. Piek, Alonso Mateos, Jan-Henk E. Dambrink, Fernando Alfonso, Noemí Escalera, Valentin Fuster, Jan Paul Ottervanger, Erik Lipsic, Agustín Albarrán, José Luis Zamorano, Francisco Fernández-Avilés, Arnoud W J van 't Hof, Saman Rasoul, Bart J. G. L. de Smet, Alberto García-Lledó, Javier Goicolea, Evelien Kolkman, Antonio Fernández-Ortiz, Wouter Remkes, Javier Botas, Cardiology, ICaR - Ischemia and repair, Other departments, MUMC+: MA Med Staf Spec Cardiologie (9), and RS: FHML non-thematic output
- Subjects
Male ,Emergency Medical Services ,Premedication ,medicine.medical_treatment ,Enfermedad cardiovascular ,RATIONALE ,030204 cardiovascular system & hematology ,0302 clinical medicine ,DESIGN ,Medicine ,FAILURE ,030212 general & internal medicine ,Myocardial infarction ,Creatine Kinase ,ejection fraction ,Netherlands ,Metoprolol ,education.field_of_study ,Ejection fraction ,Insuficiencia cardíaca ,Middle Aged ,Injections, Intravenous ,cardiovascular system ,Cardiology ,Female ,Infarto de miocardio ,Cardiology and Cardiovascular Medicine ,TIMI ,medicine.drug ,medicine.medical_specialty ,Adrenergic beta-Antagonists ,Population ,METOPROLOL ,PROPRANOLOL ,Magnetic Resonance Imaging, Cine ,Placebo ,cardiac magnetic resonance ,CLINICAL-TRIAL ,03 medical and health sciences ,CARDIOPROTECTION ,Percutaneous Coronary Intervention ,Double-Blind Method ,Internal medicine ,Humans ,infarct size ,cardiovascular diseases ,education ,Sistema cardiovascular ,CARVEDILOL ,business.industry ,Percutaneous coronary intervention ,Arrhythmias, Cardiac ,Stroke Volume ,medicine.disease ,EFFICACY ,SIZE ,Spain ,Paro cardiaco ,ST Elevation Myocardial Infarction ,business ,Mace - Abstract
Background The impact of intravenous (IV) beta-blockers before primary percutaneous coronary intervention (PPCI) on infarct size and clinical outcomes is not well established. Objectives This study sought to conduct the first double-blind, placebo-controlled international multicenter study testing the effect of early IV beta-blockers before PPCI in a general ST-segment elevation myocardial infarction (STEMI) population. Methods STEMI patients presenting
- Published
- 2016
12. Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
- Author
-
Raffaele Piccolo, Allan Iversen, Holger Thiele, Federico Piscione, Youlan L. Gu, Gennaro Galasso, Alberto Dominguez-Rodriguez, Pedro Abreu-Gonzalez, Karim D. Mahmoud, Bart J. G. L. de Smet, Ingo Eitel, Piccolo, Raffaele, Eitel, Ingo, Galasso, Gennaro, Iversen, Allan Zeeberg, Gu, Youlan L., Dominguez-Rodriguez, Alberto, de Smet, Bart J. G. L., Mahmoud, Karim D., Abreu-Gonzalez, Pedro, Thiele, Holger, and Piscione, Federico
- Subjects
Male ,Time Factors ,Physiology ,medicine.medical_treatment ,Abciximab ,Myocardial Infarction ,PRIMARY ANGIOPLASTY ,Kaplan-Meier Estimate ,Coronary thrombosis ,Risk Factors ,Recurrence ,Monoclonal ,Odds Ratio ,Clinical endpoint ,Myocardial infarction ,Randomized Controlled Trials as Topic ,Antibodies, Monoclonal ,Diabetes Mellitu ,Middle Aged ,THROMBECTOMY ,NO-REFLOW PHENOMENON ,Treatment Outcome ,INTRAVENOUS BOLUS ABCIXIMAB ,Administration ,Cardiology ,Molecular Medicine ,Platelet aggregation inhibitor ,Administration, Intravenous ,Female ,REVASCULARIZATION ,Intravenous ,PLATELET-RICH CLOTS ,Human ,medicine.drug ,medicine.medical_specialty ,Acute myocardial infarction ,Intracoronary administration ,Aged ,Chi-Square Distribution ,Coronary Thrombosis ,Humans ,Immunoglobulin Fab Fragments ,Logistic Models ,Platelet Aggregation Inhibitors ,Proportional Hazards Models ,Diabetes Mellitus ,Percutaneous Coronary Intervention ,Pharmacology ,Coronary Thrombosi ,Logistic Model ,Time Factor ,Administration, Intravenou ,Revascularization ,Antibodies ,HYPERGLYCEMIA ,Internal medicine ,medicine ,METAANALYSIS ,Immunoglobulin Fab Fragment ,business.industry ,Platelet Aggregation Inhibitor ,Risk Factor ,MORTALITY ,Percutaneous coronary intervention ,medicine.disease ,RANDOMIZED-TRIALS ,Conventional PCI ,Proportional Hazards Model ,business - Abstract
Background: Although intracoronary abciximab failed to improve prognosis compared with intravenous route in unselected ST-segment elevation myocardial infarction (STEMI) patients, little is known about the role of intracoronary abciximab in diabetic patients.Objectives: To evaluate the efficacy of intracoronary abciximab administration in diabetic patients with STEMI undergoing primary percutaneous coronary intervention (PCI).Methods: Reperfusional and clinical outcomes of intracoronary abciximab compared with intravenous bolus abciximab according to diabetic status were evaluated in a pooled analysis of five randomized trials including 3158 STEMI patients. The primary clinical endpoint of the study was the composite of death or reinfarction at 30-day follow-up.Results: Among 584 diabetic patients (18.5%), the composite of death or reinfarction was significantly reduced with intracoronary abciximab compared to intravenous abciximab (4.7% vs. 8.8%; rate ratio [RR], 0.50; 95% confidence intervals [CI], 0.26-0.99; p = 0.04), driven by numerically lower deaths (3.7% vs. 6.4%; RR, 0.56; 95% CI, 0.26-1.20; p = 0.13). Moreover, a significant reduction in definite or probable stent thrombosis was observed in patients receiving intracoronary abciximab (1% vs. 3.5%; RR, 0.27; 95% CI, 0.07-0.99; p = 0.04). Although formal tests for interaction were not significant, no clinical benefit was apparent in the cohort of STEMI patients without diabetes (n = 2574).Conclusions: In diabetic patients with STEMI undergoing primary PCI, intracoronary abciximab may improve clinical outcomes as compared with standard intravenous use. These findings require confirmation in a dedicated randomized trial. (C) 2015 Elsevier Inc. All rights reserved.
- Published
- 2015
13. The Salmonella Enteritidis TolC outer membrane channel is essential for egg white survival
- Author
-
Bart Devreese, Ruth Raspoet, Venessa Eeckhaut, Karen Vermeulen, Yurong Wen, L. De Smet, F. Van Immerseel, Richard Ducatelle, Kunihiko Nishino, and Freddy Haesebrouck
- Subjects
Salmonella enteritidis ,Microbiology ,03 medical and health sciences ,Egg White ,Animals ,Secretion ,Gene ,Poultry Diseases ,030304 developmental biology ,Sequence Deletion ,0303 health sciences ,Salmonella Infections, Animal ,biology ,Base Sequence ,0402 animal and dairy science ,04 agricultural and veterinary sciences ,General Medicine ,biochemical phenomena, metabolism, and nutrition ,Ovotransferrin ,Antimicrobial ,040201 dairy & animal science ,embryonic structures ,biology.protein ,bacteria ,Animal Science and Zoology ,Efflux ,Bacterial outer membrane ,Chickens ,Egg white ,Bacterial Outer Membrane Proteins - Abstract
Salmonella Enteritidis has developed the potential to contaminate eggs by surviving in the antimicrobial environment of the hen's egg white. This has led to a worldwide pandemic of foodborne salmonellosis infections in humans due to the consumption of contaminated eggs and egg-derived products. The molecular mechanisms of Salmonella Enteritidis egg white survival are not fully clear. Using in vivo expression technology and promoter-reporter fusions we showed that the promoter of the tolC gene, encoding the TolC outer membrane channel that is used by multidrug efflux pumps to export harmful molecules and to secrete bacterial products, is activated by egg white at the chicken body temperature. Using a Salmonella Enteritidis tolC deletion mutant we showed that TolC has an important role in egg white survival. Chromatographic separation techniques and subsequent testing of antimicrobial activities of separated egg white fractions led to the identification of ovotransferrin as the egg white antimicrobial factor which is capable of inhibiting growth of a tolC deletion strain but not the wild type strain. We provide evidence that TolC protects Salmonella Enteritidis against ovotransferrin-mediated growth inhibition in egg white.
- Published
- 2018
14. Swinging beats : transient heart block in cardiac lymphoma
- Author
-
William R. Goodyer, Peter W. H. M. Verheggen, B. J. G. L. de Smet, Jan W. Buikema, Stefan Koudstaal, J. van ’t Sant, and E A de Vrey
- Subjects
medicine.medical_specialty ,business.industry ,Heart block ,MEDLINE ,Heart Beat ,Cardiac Lymphoma ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Cardiology ,Journal Article ,Transient (computer programming) ,Cardiology and Cardiovascular Medicine ,business ,030217 neurology & neurosurgery - Published
- 2018
15. Eaton and Littler Ligament Reconstruction for the Painful first Carpometacarpal Joint : Patient satisfaction
- Author
-
M, Schoenaers, I, Degreef, and L, De Smet
- Subjects
Adult ,Joint Instability ,Male ,Ligaments ,Carpometacarpal Joints ,Middle Aged ,Plastic Surgery Procedures ,Young Adult ,Thumb ,Musculoskeletal Pain ,Patient Satisfaction ,Humans ,Female ,Follow-Up Studies - Abstract
The ligamentous reconstruction according to Eaton and Littler (7) was designed to restore the stability of the carpometacarpal joint of the thumb. We evaluated the patients' satisfaction after an Eaton and Littler-procedure as well as possible risk factors in the development of thumb basal joint instability. A retrospective chart review and clinical assessment or telephone survey are executed in 33 patients, with a mean follow-up of 7 years. Only 45% of the patients were satisfied. Within the group of clinical assessed patients, there were significant differences in thumb function comparing operated with not operated side. Overall joint hypermobility can be a contributing factor for this thumb basal joint instability, but has no effect on the outcome after an Eaton-Littler procedure.
- Published
- 2018
16. Soluble interleukin 6 receptor levels are associated with reduced myocardial reperfusion after percutaneous coronary intervention for acute myocardial infarction
- Author
-
Hilde E. Groot, Minke H. T. Hartman, Pim van der Harst, Youlan L. Gu, Ad F. M. van den Heuvel, Bart J. G. L. de Smet, Erik Lipsic, and Cardiovascular Centre (CVC)
- Subjects
Male ,Time Factors ,Heart disease ,medicine.medical_treatment ,PRIMARY ANGIOPLASTY ,Myocardial Infarction ,Biochemistry ,Leukocytes ,Immunology and Allergy ,Medicine ,Myocardial infarction ,Ultrasonography ,RISK ,INDIVIDUAL PARTICIPANT METAANALYSIS ,biology ,Hematology ,Middle Aged ,NO-REFLOW PHENOMENON ,C-Reactive Protein ,Cardiology ,Regression Analysis ,CLINICAL-IMPLICATIONS ,Female ,TIMI ,medicine.medical_specialty ,Immunology ,Myocardial Reperfusion ,HEART-DISEASE ,BLUSH GRADE ,Percutaneous Coronary Intervention ,LEFT-VENTRICULAR FUNCTION ,Internal medicine ,Humans ,cardiovascular diseases ,Interleukin 6 ,Molecular Biology ,Platelet Count ,business.industry ,C-reactive protein ,Percutaneous coronary intervention ,medicine.disease ,Receptors, Interleukin-6 ,Solubility ,Case-Control Studies ,Multivariate Analysis ,Conventional PCI ,No reflow phenomenon ,biology.protein ,ANGIOGRAPHIC ASSESSMENT ,Soluble interleukin-6 receptor ,business - Abstract
Aims: Interleukin-6 receptor (IL-6R) signalling has been suggested to play a causal role in the development and outcome of coronary heart disease (CHD). The aim of this study was to investigate the association of sIL-6R levels with myocardial reperfusion after percutaneous coronary intervention (PCI) for acute ST-elevated myocardial infarction (STEMI).Methods: Blood was sampled from 70 patients presenting with STEMI at 6 different time-points (baseline, post-PCI, t = 1 h, t = 6 h, t = 24 h, t = 2w). Coronary angiograms post-PCI were analysed for myocardial blush grade (MBG) as indicator of myocardial reperfusion. Serum IL-6 and sIL-6R were measured using IL-6 and sIL-6R enzyme-linked immunosorbent assays (ELISA).Results: sIL-6R levels fluctuated biphasic during the two weeks after STEMI. Reduced MBG was associated with a larger change in sIL-6R levels between baseline and post-PCI compared to optimal MBG (-13.40; SEM 2.78 ng/ml vs -1.99; SEM 2.35 ng/ml, respectively; p Conclusions: sIL-6R levels fluctuate biphasic during the two weeks after MI with larger changes and increased IL-6/sIL-6R ratio in patients with reduced MBG. Further research is needed to increase our understanding of the possible causality of these associations. (C) 2015 Elsevier Ltd. All rights reserved.
- Published
- 2015
17. Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial
- Author
-
Bart J. G. L. de Smet, Jeroen Vos, Paul W.A. Janssen, Johannes C. Kelder, Mathias Vrolix, Guus B. R. Brueren, Jurriën M. ten Berg, Kristoff Cornelis, Carlos Van Mieghem, Nicoline J. Breet, Willem Dewilde, Tom Adriaenssens, Tommy Vandendriessche, Freek W.A. Verheugt, and WOEST Study Investigators
- Subjects
Male ,Time Factors ,medicine.medical_treatment ,Vascular damage Radboud Institute for Health Sciences [Radboudumc 16] ,bridging ,Administration, Oral ,Kaplan-Meier Estimate ,VALVULAR HEART-DISEASE ,THERAPY ,ANGIOGRAPHY ,law.invention ,Randomized controlled trial ,law ,Risk Factors ,Antithrombotic ,atrial fibrillation ,Myocardial infarction ,Prospective Studies ,mechanical heart valve ,Prospective cohort study ,Atrial fibrillation ,Middle Aged ,EUROPEAN-SOCIETY ,Treatment Outcome ,triple therapy ,Female ,Stents ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,Hemorrhage ,Drug Administration Schedule ,Fibrinolytic Agents ,Predictive Value of Tests ,WARFARIN ANTICOAGULATION ,medicine ,MANAGEMENT ,Humans ,Propensity Score ,Aged ,Proportional Hazards Models ,business.industry ,Coronary Thrombosis ,percutaneous coronary intervention ,Percutaneous coronary intervention ,Anticoagulants ,oral anticoagulant therapy ,medicine.disease ,Surgery ,Regimen ,Logistic Models ,MYOCARDIAL-INFARCTION ,Conventional PCI ,INTERNATIONAL NORMALIZED RATIO ,ATRIAL-FIBRILLATION ,Human medicine ,business ,TASK-FORCE - Abstract
Item does not contain fulltext AIMS: To investigate the optimal periprocedural antithrombotic strategy in patients on long-term oral anticoagulation (OAC) who require percutaneous coronary intervention with stenting. METHODS AND RESULTS: The WOEST study was a randomised controlled trial which recruited 573 patients on long-term OAC who underwent PCI. The periprocedural treatment strategy was left to the operator's discretion. To assess the safety and feasibility of uninterrupted oral anticoagulation (UAC) and bridging therapy (BT), bleeding complications and MACCE were assessed in patients treated according to UAC (n=241) and BT (n=322) regimen. After 30 days, as well as after one year, there were no significant differences in bleeding complications (HR 1.14, 95% CI: 0.77-1.69, p=0.51, and HR 1.26, 95% CI: 0.94-1.69, p=0.12, respectively) and MACCE. MACCE tended to be less frequent in the UAC group (respectively HR 0.48, 95% CI: 0.15-1.51, p=0.21, and HR 0.72, 95% CI: 0.46-1.14, p=0.16). Additionally, adjustment with a propensity score revealed no significant differences. Periprocedural INR was not associated with bleeding or MACCE. CONCLUSIONS: In the WOEST study, UAC was not associated with an increase of bleeding or MACCE compared to bridging therapy. This is the largest study up to now to support the current guidelines. The WOEST trial is registered with ClinicalTrials.gov, number NCT00769938.
- Published
- 2015
18. Rationale and design of a double-blind, multicenter, randomized, placebo-controlled clinical trial of early administration of intravenous β-blockers in patients with ST-elevation myocardial infarction before primary percutaneous coronary intervention
- Author
-
Elvin Kedhi, Vicente Sánchez-Brunete, Vincent Roolvink, Arnoud W J van 't Hof, Valentin Fuster, Saman Rasoul, Iwan C. C. van der Horst, Jan-Henk E. Dambrink, Jan Paul Ottervanger, Erik Lipsic, Jan J. Piek, Borja Ibanez, A T Marcel Gosselink, Bart J. G. L. de Smet, Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), Cardiovascular Centre (CVC), Amsterdam Cardiovascular Sciences, and Cardiology
- Subjects
medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,Adrenergic beta-Antagonists ,PROPRANOLOL ,Myocardial Infarction ,Placebo ,law.invention ,CARDIOPROTECTION ,Necrosis ,Percutaneous Coronary Intervention ,Double-Blind Method ,Randomized controlled trial ,law ,Early Medical Intervention ,Internal medicine ,medicine ,Clinical endpoint ,FAILURE ,Humans ,cardiovascular diseases ,Myocardial infarction ,Ventricular remodeling ,EARLY METOPROLOL ,Metoprolol ,CARVEDILOL ,CARDIAC MAGNETIC-RESONANCE ,Ventricular Remodeling ,business.industry ,Myocardium ,ADRENERGIC-BLOCKADE ,Percutaneous coronary intervention ,EFFICACY ,medicine.disease ,Combined Modality Therapy ,Magnetic Resonance Imaging ,REDUCTION ,SIZE ,Treatment Outcome ,Conventional PCI ,Cardiology ,Administration, Intravenous ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
Background beta-Blockers have a class 1a recommendation in the treatment of patients with ST-elevation myocardial infarctions (STEMIs), as they are associated with a reduced mortality, recurrent myocardial infarction, life-threatening arrhythmias, and with prevention of unfavorable left ventricular remodeling. Whether early administration before primary percutaneous coronary intervention (PCI) of intravenous beta-blockers reduces the infarct size in the current era is unknown.Hypothesis We postulate that the early administration of beta-blockers will reduce the myocardial infarcted area as assessed by magnetic resonance imaging (MRI) at 30 days.Design In a multinational, multicenter, double-blind, placebo-controlled, randomized trial, patients with symptoms and signs of STEMI and transferred to a hospital for primary PCI will be randomized in a 1:1 fashion to intravenous metoprolol (5 mg twice daily) administration or placebo. Before admission, study treatment will be started as soon as possible after the diagnosis of STEMI. After admission, primary PCI will be performed as per standard of care. After primary PCI, medical treatment will occur as per current guidelines in all patients, including the use of oral beta-blockers. The primary end point is the myocardial infarct size as assessed by MRI at 30 days. Based on a superiority design and assuming an 18% relative infarct size reduction (from 28% to 23.5%), 408 patients are required to be enrolled, accounting for 20% drop-out (alpha =.05 and power = 80%).Summary The EARLY-BAMI trial is a multinational, multicenter, double-blind, placebo-controlled, randomized clinical trial that will investigate the impact of intravenous metoprolol administration before primary PCI for STEMI on myocardial infarct size as measured with MRI at 30 days.
- Published
- 2014
19. Effects of Baseline Coronary Occlusion and Diabetes Mellitus in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
- Author
-
Raffaele Piccolo, Federico Piscione, Pedro Abreu-Gonzalez, Allan Iversen, Bruno Trimarco, Gennaro Galasso, Alberto Dominguez-Rodriguez, Youlan L. Gu, Karim D. Mahmoud, Holger Thiele, Bart J. G. L. de Smet, Ingo Eitel, Piccolo, Raffaele, Galasso, Gennaro, Iversen, Allan Zeeberg, Eitel, Ingo, Dominguez Rodriguez, Alberto, Gu, Youlan L, de Smet, Bart J. G. L, Mahmoud, Karim D, Abreu Gonzalez, Pedro, Trimarco, Bruno, Thiele, Holger, and Piscione, Federico
- Subjects
Male ,medicine.medical_treatment ,Abciximab ,FLOW ,Myocardial Infarction ,PRIMARY ANGIOPLASTY ,Coronary Angiography ,HORIZONS-AMI ,Electrocardiography ,Risk Factors ,Occlusion ,Monoclonal ,Medicine ,REPERFUSION ,Myocardial infarction ,Coronary Vessel ,Medicine (all) ,Incidence ,Aged ,Antibodies, Monoclonal ,Coronary Occlusion ,Coronary Vessels ,Diabetes Mellitus ,Europe ,Female ,Humans ,Immunoglobulin Fab Fragments ,Injections, Intra-Arterial ,Middle Aged ,Platelet Aggregation Inhibitors ,Platelet Glycoprotein GPIIb-IIIa Complex ,Preoperative Care ,Prognosis ,Survival Rate ,Thrombolytic Therapy ,Percutaneous Coronary Intervention ,Cardiology and Cardiovascular Medicine ,Diabetes Mellitu ,Thrombolysis ,INTRAVENOUS BOLUS ABCIXIMAB ,Cardiology ,Platelet aggregation inhibitor ,Ticagrelor ,TIMI ,medicine.drug ,Human ,medicine.medical_specialty ,Prognosi ,Antibodies ,Injections ,Internal medicine ,TICAGRELOR ,cardiovascular diseases ,Immunoglobulin Fab Fragment ,business.industry ,Intra-Arterial ,Platelet Aggregation Inhibitor ,Risk Factor ,MORTALITY ,Percutaneous coronary intervention ,INTRACORONARY ,medicine.disease ,RANDOMIZED-TRIALS ,THROMBOLYTIC THERAPY ,Coronary occlusion ,business - Abstract
Several studies have highlighted the prognostic role of preprocedural Thrombolysis In Myocardial Infarction (TIMI) flow in the infarct-related artery (IRA) in patients with ST-segment elevation myocardial infarction (STEMI). However, the impact of preprocedural IRA occlusion in patients with diabetes with STEMI has been insufficiently studied. The aim of this study was to evaluate the effects of baseline IRA occlusion and diabetic status in patients with STEMI who underwent primary percutaneous coronary intervention by using data from a pooled analysis of randomized trials comparing intracoronary with intravenous abciximab bolus administration. A total of 3,046 patients with STEMI who underwent primary percutaneous coronary intervention were included. Diabetes was present in 578 patients (19%). The primary outcome was mortality after a median follow-up period of 375 days. Secondary end points were reinfarction and stent thrombosis. In patients without diabetes, IRA occlusion versus no occlusion was not associated with increased rates of mortality (4.3% vs 2.7%, p = 0.051) and reinfarction (3.3% vs 2.5%, p = 0.33). Patients with diabetes with IRA occlusion compared with those without occlusion showed higher rates of mortality (10.6% vs 4.6%, p = 0.01) and reinfarction (5.6% vs 2.1%, p = 0.03). Baseline IRA occlusion increased the rate of stent thrombosis in the nondiabetic (2.1% vs 1.0%, p = 0.04) and diabetic (3.2% vs 0.8%, p = 0.05) cohorts. Interaction analysis demonstrated that the risk for death and reinfarction was significantly increased when diabetes and IRA occlusion occurred concomitantly. In conclusion, patients with STEMI with diabetes and baseline IRA occlusion had disproportionately higher rates of death and reinfarction. Preprocedural IRA occlusion increased the risk for stent thrombosis, irrespective of diabetic status. (C) 2014 Elsevier Inc. All rights reserved.
- Published
- 2014
20. Effect of Metformin on Left Ventricular Function After Acute Myocardial Infarction in Patients Without Diabetes The GIPS-III Randomized Clinical Trial
- Author
-
Chris P H, Lexis, Iwan C C, van der Horst, Erik, Lipsic, Wouter G, Wieringa, Rudolf A, de Boer, Ad F M, van den Heuvel, Hindrik W, van der Werf, Remco A J, Schurer, Gabija, Pundziute, Eng S, Tan, Wybe, Nieuwland, Hendrik M, Willemsen, Bernard, Dorhout, Barbara H W, Molmans, Anouk N A, van der Horst-Schrivers, Bruce H R, Wolffenbuttel, Gert J, ter Horst, Albert C, van Rossum, Jan G P, Tijssen, Hans L, Hillege, Bart J G L, de Smet, Pim, van der Harst, Dirk J, van Veldhuisen, Fred, van den Berg, Cardiology, ICaR - Heartfailure and pulmonary arterial hypertension, Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), Cardiovascular Centre (CVC), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Life Course Epidemiology (LCE), Lifestyle Medicine (LM), Center for Liver, Digestive and Metabolic Diseases (CLDM), and Groningen Kidney Center (GKC)
- Subjects
Male ,medicine.medical_specialty ,PROGNOSIS ,medicine.medical_treatment ,Myocardial Infarction ,PERCUTANEOUS CORONARY INTERVENTION ,Placebo ,Ventricular Function, Left ,EVENTS ,Ventricular Dysfunction, Left ,chemistry.chemical_compound ,Double-Blind Method ,Interquartile range ,Internal medicine ,medicine ,Humans ,Hypoglycemic Agents ,Myocardial infarction ,cardiovascular diseases ,LONG-TERM TRENDS ,Aged ,business.industry ,MORTALITY ,Percutaneous coronary intervention ,General Medicine ,ASSOCIATION ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Metformin ,DYSFUNCTION ,Treatment Outcome ,chemistry ,Cardiology ,Myocardial infarction complications ,HEART-FAILURE ,Female ,REVASCULARIZATION ,Glycated hemoglobin ,business ,Mace ,medicine.drug ,TASK-FORCE - Abstract
Importance Metformin treatment is associated with improved outcome after myocardial infarction in patients with diabetes. In animal experimental studies metformin preserves left ventricular function. Objective To evaluate the effect of metformin treatment on preservation of left ventricular function in patients without diabetes presenting with ST-segment elevation myocardial infarction (STEMI). Design, Setting, and Participants Double-blind, placebo-controlled study conducted among 380 patients who underwent primary percutaneous coronary intervention (PCI) for STEMI at the University Medical Center Groningen, the Netherlands, between January 1, 2011, and May 26, 2013. Interventions Metformin hydrochloride (500 mg) (n = 191) or placebo (n = 189) twice daily for 4 months. Main Outcomes and Measures The primary efficacy measure was left ventricular ejection fraction (LVEF) after 4 months, assessed by magnetic resonance imaging. A secondary efficacy measure was the N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration after 4 months. The incidence of major adverse cardiac events (MACE; the combined end point of death, reinfarction, or target-lesion revascularization) was recorded until 4 months as a secondary efficacy measure. Results At 4 months, all patients were alive and none were lost to follow-up. LVEF was 53.1% (95% CI, 51.6%-54.6%) in the metformin group (n = 135), compared with 54.8% (95% CI, 53.5%-56.1%) ( P = .10) in the placebo group (n = 136). NT-proBNP concentration was 167 ng/L in the metformin group (interquartile range [IQR], 65-393 ng/L) and 167 ng/L in the placebo group (IQR, 74-383 ng/L) ( P = .66). MACE were observed in 6 patients (3.1%) in the metformin group and in 2 patients (1.1%) in the placebo group ( P = .16). Creatinine concentration (79 µmol/L [IQR, 70-87 µmol/L] vs 79 µmol/L [IQR, 72-89 µmol/L], P = .61) and glycated hemoglobin (5.9% [IQR, 5.6%-6.1%] vs 5.9% [IQR, 5.7%-6.1%], P = .15) were not significantly different between both groups. No cases of lactic acidosis were observed. Conclusions and Relevance Among patients without diabetes presenting with STEMI and undergoing primary PCI, the use of metformin compared with placebo did not result in improved LVEF after 4 months. The present findings do not support the use of metformin in this setting. Trial Registration clinicaltrials.gov Identifier:NCT01217307.
- Published
- 2014
21. Post-REACH 2018 assessment of in vitro skin sensitisation testing for organic substances
- Author
-
Sandy Jacobs, K. Vriens, Maaike Bilau, L. De Smet, and A. de Smedt
- Subjects
business.industry ,Medicine ,General Medicine ,Pharmacology ,Toxicology ,business ,In vitro - Published
- 2018
22. Prospective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data
- Author
-
Annouschka Laenen, Norah Lynn Henry, A. S Dieudonne, Ignace Vergote, Hans Wildiers, Johan Verhaeghe, Steven Pans, L. De Smet, B. Van Calster, Robert Paridaens, K. Verschueren, M-R Christiaens, M. Van Hoydonck, Rene Westhovens, Karin Leunen, Anneleen Lintermans, Patrick Neven, D. Timmerman, and Leilani Morales
- Subjects
medicine.medical_specialty ,Antineoplastic Agents, Hormonal ,medicine.drug_class ,Breast Neoplasms ,Cohort Studies ,Tendons ,Grip strength ,Breast cancer ,Hand strength ,Internal medicine ,medicine ,Humans ,Musculoskeletal Diseases ,Prospective Studies ,skin and connective tissue diseases ,Prospective cohort study ,Aged ,Aromatase inhibitor ,Hand Strength ,Aromatase Inhibitors ,business.industry ,Synovial Membrane ,Hematology ,Middle Aged ,medicine.disease ,Surgery ,Postmenopause ,body regions ,Tamoxifen ,Tendon sheath ,Oncology ,Chemotherapy, Adjuvant ,Female ,business ,Follow-Up Studies ,Cohort study ,medicine.drug - Abstract
Background Aromatase inhibitors (AIs) frequently lead to the AI-induced musculoskeletal syndrome (AIMSS). Looking into its pathophysiology, 6 months of AI therapy thickens the tendon sheath with intra-articular fluid (IAF) retention and loss of grip strength. We here report 24-month follow-up data. Patients and methods A prospective cohort study of 33 postmenopausal breast cancer patients received adjuvant endocrine therapy; 27 received an AI and 6 received tamoxifen. At baseline, 6 and 24 months patients had a rheumatologic examination, including a grip strength test, and magnetic resonance imaging of both hands and wrists. The primary end point was tenosynovial changes; secondary end points were changes in morning stiffness, grip strength and IAF. Results Twenty-three AI and 5 tamoxifen patients completed all investigations. Between month 6 and 24, IAF further increased in AI users (P = 0.04) but not in tamoxifen users, and grip strength further decreased in both groups. The worsened tenosynovial changes were strongly correlated with a decrease in grip strength. At 24 months, morning stiffness continued to be present in over a third of AI users. Conclusion AIMSS represents a substantial problem in breast cancer patients. It is associated with tenosynovial changes, IAF retention, joint stiffness and loss of grip strength that do not improve with prolonged use.
- Published
- 2013
23. Long term outcome of trapeziectomy with ligament reconstruction/tendon interposition versus thumb basal joint prosthesis
- Author
-
S. Fiews, Karolien Didden, L. De Smet, Ilse Degreef, and Lore Vandenberghe
- Subjects
Male ,musculoskeletal diseases ,medicine.medical_specialty ,Time Factors ,Joint Prosthesis ,medicine.medical_treatment ,Arthritis ,Osteoarthritis ,Thumb ,Prosthesis ,Tendons ,Humans ,Medicine ,Arthroplasty, Replacement ,Cementation ,Retrospective Studies ,business.industry ,Carpometacarpal Joints ,Middle Aged ,medicine.disease ,Arthroplasty ,Osteotomy ,Tendon ,Surgery ,body regions ,Trapezium Bone ,Treatment Outcome ,medicine.anatomical_structure ,Ligaments, Articular ,Ligament ,Female ,Implant ,business - Abstract
Several surgical techniques to treat thumb basal joint arthritis have been described. In this study we compared the results of a cemented thumb basal joint with trapeziectomy with a ligament reconstruction and tendon interposition. A questionnaire was sent to all 519 patients, 322 (with 382 procedures) responded. No significant differences were found when comparing impairment, pain, patient satisfaction and disability. Given the fact that the superiority of a prosthesis cannot be proven and the cost of the implant is greater, we recommend the trapeziectomy with ligament reconstruction and tendon interposition as opposed to arthroplasty as the first choice in the treatment of basal joint osteoarthritis of the thumb.
- Published
- 2012
24. Evaluation of the metaphyseal ulnar shortening technique according to Sennwald
- Author
-
J, Beckers, B, The, I, Degreef, and L, De Smet
- Subjects
Adult ,Male ,Reoperation ,Hand Strength ,Pain ,Ulna ,Syndrome ,Middle Aged ,Wrist ,Osteotomy ,Radiography ,Young Adult ,Postoperative Complications ,Humans ,Female ,Range of Motion, Articular - Abstract
The outcome of a metaphyseal ulnar shortening osteotomy, reported by Sennwald as an alternative option for ulnar abutment syndrome, was evaluated with -regard to the functional results, pain relief and incidence of complications.We conducted a review of 12 patients ; measured parameters were DASH score, PRWE, VAS for pain, grip force and wrist motion.Only disability improved significantly with a DASH score of 42 (p = 0.03). The function and pain assessment scores did not improve in 3 patients. We found no correlation between change in functional scores and other measured variables. Six patients were reoperated for prominent screw heads or new-onset distal radioulnar joint osteoarthritis.All osteomies healed fast and uneventfully and disability improved in most patients but 25% did not improve and 50% were re-operated. Further investigation is needed to evaluate the value of the metaphyseal osteotomy as an alternative treatment for ulnar abutment syndrome.
- Published
- 2016
25. Outcome after percutaneous coronary intervention for different indications: long-term results from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
- Author
-
Stefan James, Bart J. G. L. de Smet, Per Tornvall, Mikael Aasa, Fredrik Calais, Peter Eriksson, Axel Åkerblom, Marieke L. Fokkema, Jens Jensen, Fredrik Scherstén, Bo Lagerqvist, Per Albertsson, and Iwar Sjögren
- Subjects
Male ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,Coronary Angiography ,THERAPY ,DISEASE ,Coronary artery disease ,0302 clinical medicine ,Risk Factors ,Myocardial Revascularization ,030212 general & internal medicine ,Myocardial infarction ,Registries ,Angioplasty, Balloon, Coronary ,Aged, 80 and over ,education.field_of_study ,PCI ,Middle Aged ,Treatment Outcome ,surgical procedures, operative ,myocardial infarction ,TRIALS ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,coronary artery disease ,Adult ,medicine.medical_specialty ,Population ,Time ,STEMI ,03 medical and health sciences ,Angioplasty ,Internal medicine ,STENT THROMBOSIS ,medicine ,Humans ,cardiovascular diseases ,STRATEGY ,education ,Aged ,Sweden ,indications ,business.industry ,Unstable angina ,percutaneous coronary intervention ,ELEVATION MYOCARDIAL-INFARCTION ,Percutaneous coronary intervention ,ST-ELEVATION ,medicine.disease ,Surgery ,Heart failure ,Conventional PCI ,prognosis ,business - Abstract
Aims: The aim of this study was to evaluate clinical outcome for different indications for PCI in an unselected, nationwide PCI population at short- and long-term follow-up.Methods and results: We evaluated clinical outcome up to six years after PCI in all patients undergoing a PCI procedure for different indications in Sweden between 2006 and 2010. A total of 70,479 patients were treated for stable coronary artery disease (CAD) (21.0%), unstable angina (11.0%), non-ST-elevation myocardial infarction (NSTEMI) (36.6%) and ST-elevation myocardial infarction (STEMI) (31.4%). Mortality was higher in STEMI patients at one year after PCI (9.6%) compared to NSTEMI (4.7%), unstable angina (2.2%) and stable CAD (2.0%). At one year after PCI until the end of follow-up, the adjusted mortality risk (one to six years after PCI) and the risk of myocardial infarction were comparable between NSTEMI and STEMI patients and lower in patients with unstable angina and stable CAD. The adjusted risk of stent thrombosis and heart failure was highest in STEMI patients.Conclusions: The risk of short-term mortality, heart failure and stent thrombosis is highest for STEMI patients after PCI. Therapies to reduce stent thrombosis and heart failure appear to be most important in decreasing mortality in patients with STEMI or NSTEMI undergoing PCI.
- Published
- 2016
26. Pooled Analysis Comparing the Efficacy of Intracoronary Versus Intravenous Abciximab in Smokers Versus Nonsmokers Undergoing Primary Percutaneous Coronary Revascularization for Acute ST-Elevation Myocardial Infarction
- Author
-
Federico Piscione, Gennaro Galasso, Stephan Windecker, Ingo Eitel, Holger Thiele, Alberto Dominguez-Rodriguez, Bart J. G. L. de Smet, Youlan L. Gu, Allan Iversen, Raffaele Piccolo, Pedro Abreu-Gonzalez, Giovanni Esposito, Piccolo, Raffaele, Galasso, Gennaro, Eitel, Ingo, Dominguez Rodriguez, Alberto, Iversen, Allan Zeeberg, Gu, Youlan L, Abreu Gonzalez, Pedro, de Smet, Bart J. G. L, Esposito, Giovanni, Windecker, Stephan, Thiele, Holger, and Piscione, Federico
- Subjects
Male ,IMPACT ,Abciximab ,medicine.medical_treatment ,STENT ,Enfermedad cardiovascular ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,BOLUS ABCIXIMAB ,0302 clinical medicine ,Monoclonal ,Adult ,Aged ,Antibodies, Monoclonal ,Case-Control Studies ,Female ,Humans ,Immunoglobulin Fab Fragments ,Injections, Intra-Arterial ,Injections, Intravenous ,Middle Aged ,Percutaneous Coronary Intervention ,Platelet Aggregation Inhibitors ,Proportional Hazards Models ,Randomized Controlled Trials as Topic ,ST Elevation Myocardial Infarction ,Smoking ,Treatment Outcome ,Cardiology and Cardiovascular Medicine ,030212 general & internal medicine ,Myocardial infarction ,AMI TRIAL ,610 Medicine & health ,Hazard ratio ,PARADOX ,Cardiology ,Platelet aggregation inhibitor ,RANDOMIZED CLINICAL-TRIALS ,Intravenous ,INTERVENTION ,medicine.drug ,medicine.medical_specialty ,Cardiología ,Lower risk ,Antibodies ,Injections ,03 medical and health sciences ,Internal medicine ,medicine ,METAANALYSIS ,Intra-Arterial ,business.industry ,Percutaneous coronary intervention ,Stent ,medicine.disease ,THROMBOSIS ,Tabaco ,Conventional PCI ,business - Abstract
Cigarette smokers with ST-segment elevation myocardial infarction (STEMI) may present different response to potent antithrombotic therapy compared to nonsmokers. We assessed the impact of smoking status and intracoronary abciximab in patients with STEMI undergoing primary percutaneous coronary intervention (PCI). We pooled data from 5 randomized trials comparing intracoronary versus intravenous abciximab bolus in patients undergoing primary PCI. The primary end point was the composite of death or reinfarction at a mean follow-up of 292 ± 138 days. Of 3,158 participants, 1,369 (43.3%) were smokers, and they had a lower risk of the primary end point in crude, but not in adjusted analyses (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.63 to 1.21, p = 0.405). Intracoronary versus intravenous abciximab was associated with a significant reduction in the risk of primary end point among smokers (3.6% vs 8.0%; HR 0.43, 95% CI 0.26 to 0.72, p = 0.001), but not in nonsmokers (10.2% vs 9.9%; HR 0.99, 95% CI 0.72 to 1.36, p = 0.96), with a significant interaction (p = 0.009). Furthermore, intracoronary abciximab decreased the risk of reinfarction in smokers (HR 0.30, 95% CI 0.15 to 0.62, p = 0.001), with no difference in nonsmokers (HR 1.20, 95% CI 0.71 to 2.01, p = 0.50). Stent thrombosis was lowered by intracoronary abciximab in smokers (HR 0.28, 95% CI 0.06 to 0.66, p = 0.009), but was ineffective in nonsmokers (HR 1.04, 95% CI 0.54 to 2.00, p = 0.903). Interaction testing showed heterogeneity in treatment effect for reinfarction (p = 0.002) and stent thrombosis (p = 0.018) according to smoking status. In conclusion, among patients with STEMI undergoing primary PCI, smoking status did not affect the adjusted risk of clinical events. Intracoronary abciximab bolus improved clinical outcomes by reducing the risk of death or reinfarction. Sin financiación 3.398 JCR (2016) Q2, 47/126 Cardiac & Cardiovascular Systems UEC
- Published
- 2016
27. Metformin in non-Diabetic Patients Presenting with ST Elevation Myocardial Infarction: Rationale and Design of the Glycometabolic Intervention as Adjunct to Primary Percutaneous Intervention in ST Elevation Myocardial Infarction (GIPS)-III Trial
- Author
-
Chris P. H. Lexis, Albert C. van Rossum, Bruce H. R. Wolffenbuttel, Pim van der Harst, Rudolf A. de Boer, Bart J. G. L. de Smet, Iwan C. C. van der Horst, Anouk N A van der Horst-Schrivers, Erik Lipsic, Dirk J. van Veldhuisen, Cardiology, ICaR - Heartfailure and pulmonary arterial hypertension, Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), Cardiovascular Centre (CVC), Faculteit Medische Wetenschappen/UMCG, Life Course Epidemiology (LCE), Lifestyle Medicine (LM), Guided Treatment in Optimal Selected Cancer Patients (GUTS), and Center for Liver, Digestive and Metabolic Diseases (CLDM)
- Subjects
Cardiac function curve ,Left ventricular ejection fraction ,medicine.medical_specialty ,medicine.medical_treatment ,Myocardial Infarction ,Heart failure ,Article ,Ventricular Function, Left ,CARDIOPROTECTION ,Ventricular Dysfunction, Left ,Percutaneous Coronary Intervention ,LEFT-VENTRICULAR FUNCTION ,Internal medicine ,medicine ,Humans ,Hypoglycemic Agents ,Pharmacology (medical) ,cardiovascular diseases ,Myocardial infarction ,REPERFUSION INJURY ,Cardiac remodeling ,IMPROVES CARDIAC-FUNCTION ,Pharmacology ,Cardioprotection ,Ejection fraction ,business.industry ,SEGMENT ELEVATION ,MORTALITY ,ACTIVATED PROTEIN-KINASE ,Electrocardiography in myocardial infarction ,Percutaneous coronary intervention ,General Medicine ,Glucose Tolerance Test ,medicine.disease ,Metformin ,ST-elevation myocardial infarction ,cardiovascular system ,Cardiology ,HEART-FAILURE ,PERMEABILITY TRANSITION PORE ,GLYCATION END-PRODUCTS ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
Background Left ventricular dysfunction and the development of heart failure is a frequent and serious complication of myocardial infarction. Recent animal experimental studies suggested that metformin treatment reduces myocardial injury and preserves cardiac function in non-diabetic rats after experimental myocardial infarction. We will study the efficacy of metformin with the aim to preserve left ventricular ejection fraction in non-diabetic patients presenting with ST elevation myocardial infarction (STEMI). Methods The Glycometabolic Intervention as adjunct to Primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial is a prospective, single center, double blind, randomized, placebo-controlled trial. Three-hundred-and-fifty patients, without diabetes, requiring primary percutaneous coronary intervention (PCI) for STEMI will be randomized to metformin 500 mg twice daily or placebo treatment and will undergo magnetic resonance imaging (MRI) after 4 months. Major exclusion criteria were prior myocardial infarction and severe renal dysfunction. The primary efficacy parameter is left ventricular ejection fraction 4 months after randomization. Secondary and tertiary efficacy parameters include major adverse cardiac events, new onset diabetes and glycometabolic parameters, and echocardiographic diastolic function. Safety parameters include renal function deterioration and lactic acidosis. Conclusions The GIPS-III trial will evaluate the efficacy of metformin treatment to preserve left ventricular ejection fraction in STEMI patients without diabetes.
- Published
- 2012
28. How should I treat an ostial thrombotic occlusion of the right coronary artery in the setting of an acute myocardial infarction?
- Author
-
Ruken Bengi Bakal, Mamas A. Mamas, Gabya Pundziute, Guliz Erdem, Cemil Izgi, Hasan Feray, and Bart J. G. L. de Smet
- Subjects
medicine.medical_specialty ,business.industry ,Coronary Thrombosis ,medicine.medical_treatment ,Myocardial Infarction ,medicine.disease ,Thrombosis ,Thrombotic occlusion ,Internal medicine ,Right coronary artery ,medicine.artery ,Angioplasty ,medicine ,Cardiology ,Humans ,Female ,Myocardial infarction ,Angioplasty, Balloon, Coronary ,Cardiology and Cardiovascular Medicine ,business ,Aged - Published
- 2012
29. Clinical advances in imaging: how useful is computed tomography for guiding and evaluating cardiac interventions
- Author
-
Tineke P. Willems, Wouter G. Wieringa, Gabija Pundziute, and Bart J. G. L. de Smet
- Subjects
Aortic valve ,medicine.medical_specialty ,Noninvasive imaging ,medicine.diagnostic_test ,business.industry ,Computed tomography ,Multislice computed tomography ,Chest pain ,medicine.disease ,Coronary artery disease ,medicine.anatomical_structure ,Internal medicine ,Cardiac interventions ,Mitral valve ,medicine ,Cardiology ,Radiology ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business - Abstract
Multislice computed tomography (MSCT) has emerged as a noninvasive imaging modality allowing anatomical imaging of the heart. The presence of coronary artery stenosis can be reliably ruled out, without development of cardiovascular events on follow-up, which currently makes MSCT particularly useful for the evaluation of patients with chest pain and low-to-intermediate pretest likelihood of coronary artery disease. In addition, MSCT may be useful for guiding interventions such as those for cardiac valves or treating cardiac rhythm disorders. Since the technology behind MSCT continues to evolve at a rapid pace and the radiation doses decrease, further expansion of the applications of MSCT across the clinical practices is expected.
- Published
- 2011
30. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis
- Author
-
N.L. Henry, Leilani Morales, Steven Pans, B. Van Calster, L. De Smet, Johan Verhaeghe, Dirk Timmerman, Karin Leunen, A. S Dieudonne, M. Van Hoydonck, Patrick Neven, Rene Westhovens, Ignace Vergote, Hans Wildiers, Anneleen Lintermans, M-R Christiaens, Robert Paridaens, and K. Verschueren
- Subjects
medicine.medical_specialty ,Neoplasms, Hormone-Dependent ,medicine.drug_class ,Urology ,Breast Neoplasms ,Anastrozole ,Body Mass Index ,Cohort Studies ,Grip strength ,Breast cancer ,Internal medicine ,Nitriles ,medicine ,Humans ,Musculoskeletal Diseases ,Aromatase ,Prospective cohort study ,Aged ,Aromatase inhibitor ,Hand Strength ,biology ,Aromatase Inhibitors ,business.industry ,Syndrome ,Hematology ,Middle Aged ,Triazoles ,medicine.disease ,Arthralgia ,Confidence interval ,Androstadienes ,Postmenopause ,Tamoxifen ,Endocrinology ,Oncology ,Letrozole ,biology.protein ,Female ,business ,Body mass index ,medicine.drug - Abstract
Background Our preliminary results showed that tenosynovial changes and decrease in grip strength are associated with the aromatase inhibitor-induced musculoskeletal syndrome (AIMSS). Here, we report the final results and assess the relationship between grip strength and body mass index (BMI). Patients and methods We conducted a prospective study including postmenopausal early breast cancer patients receiving either an aromatase inhibitor (AI) or tamoxifen. Primary end point was change from baseline in tenosynovial abnormalities. Secondary end points were changes from baseline in morning stiffness, intra-articular fluid and grip strength and its association with BMI. Results After 6 months of therapy, 74% [95% confidence interval (CI) 51% to 89%] of AI-treated patients had worsened tenosynovial abnormalities, 56% (95% CI 34% to 75%) had increased intra-articular fluid, and 22% (95% CI 9% to 45%) had increased morning stiffness. Grip strength decreased 8% for the left hand (95% CI 2% to 21%) and 11% for the right (95% CI 4% to 17%). Regression analysis suggested that grip strength decreased more for subjects with high or with low BMI. Conclusions AIMSS is characterized by tenosynovial changes, intra-articular fluid and morning stiffness. We hypothesize that the quadratic association between BMI and loss of grip strength reflects AI-induced changes on the endocrine control of the growth hormone insulin-like growth factor-I pathway.
- Published
- 2011
31. A biomechanical study on fracture risks in ulnohumeral arthroplasty
- Author
-
Thomas Boogmans, L. De Smet, Ilse Degreef, and R. Van Audekercke
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Perforation (oil well) ,Ulna ,Arthroplasty ,Fractures, Bone ,Cadaver ,Elbow Joint ,Humans ,Medicine ,Orthopedics and Sports Medicine ,Humerus ,Aged ,Aged, 80 and over ,Orthodontics ,business.industry ,Biomechanics ,General Medicine ,Biomechanical Phenomena ,Surgery ,Diaphysis ,medicine.anatomical_structure ,Female ,Diaphyses ,Stress, Mechanical ,business ,Cadaveric spasm - Abstract
In the Outerbridge-Kashiwagi ulnohumeral arthroplasty, bone strength may be weakened significantly as a result of the humeral fenestration. Therefore, fracture risks may be increased, particularly in the immediate postoperative period. The objective of this biomechanical cadaver study is to study the humeral bone strength after ulnohumeral arthroplasty. A biomechanical cadaveric study was done in which differences in force needed to fracture the humerus with and without fenestration was measured. First, the diaphysis of 12 distal humeri was embedded and a posterior force was applied until a fracture occurred. Second, a similar study was done with fixed humeral columns, to specifically compare the column strength. In the first part, the force needed to fracture was reduced by 17% after ulnohumeral arthroplasty, which was not statistically significant. However, a shift in the fracture pattern occurred: from diaphyseal fracture towards column fractures after the arthroplasty. In the second part, the force needed to fracture the columns proved to be significantly reduced by 41% after humeral perforation. Alterations in the biomechanical properties of the distal humerus after ulnohumeral arthroplasty may lead to a shift in fracture patterns from diaphyseal to column fractures. The strength of the columns is strongly reduced by 41%.
- Published
- 2011
32. Operator dependence of outcome after primary percutaneous coronary intervention
- Author
-
Eng-Shiong Tan, Pieter J. Vlaar, Hans L. Hillege, Felix Zijlstra, Rutger L. Anthonio, Bart J. G. L. de Smet, Gillian A.J. Jessurun, Ad F. M. van den Heuvel, Life Course Epidemiology (LCE), Cardiovascular Centre (CVC), and Groningen Kidney Center (GKC)
- Subjects
Male ,medicine.medical_treatment ,Myocardial Infarction ,PRIMARY ANGIOPLASTY ,Coronary Angiography ,law.invention ,Atherectomy ,Randomized controlled trial ,law ,Odds Ratio ,Clinical endpoint ,risk factors ,REPERFUSION ,Medicine ,ST-SEGMENT ELEVATION ,Prospective Studies ,Myocardial infarction ,Angioplasty, Balloon, Coronary ,THROMBUS ASPIRATION ,Netherlands ,Thrombectomy ,medicine.diagnostic_test ,Myocardial Perfusion Imaging ,Middle Aged ,Outcome and Process Assessment, Health Care ,Treatment Outcome ,Motor Skills ,MORTALITY DATA ,Cardiology ,Female ,Stents ,Clinical Competence ,Cardiology and Cardiovascular Medicine ,safety ,ACUTE MYOCARDIAL-INFARCTION ,medicine.medical_specialty ,Suction ,Risk Assessment ,STEMI ,Myocardial perfusion imaging ,TRANSFUSION ,Coronary Circulation ,Internal medicine ,Angioplasty ,Humans ,Aged ,Analysis of Variance ,Chi-Square Distribution ,business.industry ,Percutaneous coronary intervention ,PERFORMANCE ,medicine.disease ,FUNNEL PLOTS ,Conventional PCI ,UPDATE ,business - Abstract
Aims: Primary percutaneous coronary intervention (PCI) is a widely practised therapeutic procedure to treat ST-elevation myocardial infarction (STEM l). However, a significant proportion of patients undergoing primary PCI suffers from adverse events, such as incomplete myocardial reperfusion. It is currently unknown to which degree these adverse events are operator related. Methods and results: We investigated inter-operator variation using objective safety and efficacy endpoints during primary PCI for STEM I. All PCIs were performed by six experienced interventional cardiologists as part of a randomised single centre trial. The primary endpoint of this study was optimal myocardial reperfusion (myocardial blush grade 3 [MBG]). All 1,071 patients enrolled in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS) were included in this analysis. In the six operator groups, the rate of the primary endpoint MBG 3 ranged between 29.2% and 55.5%. The variable for operators remained significantly associated with MBG 3 after adjustment for baseline and procedural differences. There were no statistical differences observed with regard to safety endpoints. Conclusions: This study illustrates the observation that even in a controlled setting significant inter-operator variation may exist in the efficacy of primary PCI. This study supports the routine collection of high-quality datasets to evaluate and improve individual operator competence and skills.
- Published
- 2011
33. Métodos terapéuticos: artroscopia de muñeca
- Author
-
L. De Smet
- Subjects
Physics ,Humanities - Abstract
La artroscopia es la prueba de referencia para numerosos trastornos intraarticulares. El desarrollo de un material adecuado ha permitido mejorar los procedimientos terapeuticos. Es el caso de lesiones del fibrocartilago triangular (cronicas o agudas), cuerpos extranos y artritis septicas. Para las fracturas intraarticulares del radio distal, la artroscopia es un metodo excelente para evaluar la alineacion de la superficie radial. La reseccion de la estiloides radial y los gangliones dorsales y palmares ha sido posible gracias a las tecnicas artroscopicas.
- Published
- 2009
34. Dupuytren’s Disease: a Predominant Reason for Elective Finger Amputation in Adults
- Author
-
Ilse Degreef and L. De Smet
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Disease ,Young Adult ,Finger amputation ,medicine ,Humans ,Young adult ,Aged ,Pain Measurement ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Hand surgery ,Retrospective cohort study ,General Medicine ,Middle Aged ,Surgery ,Dupuytren Contracture ,body regions ,medicine.anatomical_structure ,Amputation ,Elective Surgical Procedures ,Upper limb ,Female ,business ,Elective Surgical Procedure - Abstract
Dupuytren's disease (DD) can lead to severe disabling finger contractures resistant to surgical treatment. In some cases, finger or ray amputation is considered, due to a severe functional deficit or vascular injury. To evaluate the weight of amputation surgery in DD, a retrospective study was conducted over a 5-year time interval, outlining all indications for elective finger amputation and its prevalence in the total of surgical interventions for DD. The outcome in DD was compared to post-traumatic amputations. Out of 31 elective finger and ray amputations, 12 (39%) were indicated for DD, all in the 4th or 5th ray, of which 92% were in recurrent disease. In the 646 surgical procedures for DD in the matching time interval, we conclude that almost 2% were elective amputations. The outcome of amputation in DD was similar to post-traumatic amputations. Based on these data, we feel that patients should be informed that sometimes, surgical treatment for Dupuytren's disease can lead to an eventual decision to amputate.
- Published
- 2009
35. Artroscopia de muñeca. Técnica, características normales
- Author
-
L. De Smet
- Subjects
Philosophy ,Humanities - Abstract
La artroscopia de muneca es una herramienta importante en la exploracion de esta articulacion, pese a sus limites y posibles complicaciones. Se debe realizar la exploracion con una tecnica adecuada, prestando especial atencion a las vias de acceso y los movimientos intraarticulares, pruebas dinamicas y drenajes. La exploracion debe ser exhaustiva, empleando un listado de chequeo. El conocimiento de la anatomia y sus variantes, los procesos normales de envejecimiento, los tipos de lesion y el reconocimiento de las especificidades de cada enfermedad son la piedra angular de un estudio eficaz.
- Published
- 2009
36. Prevalence of work related upper limb disorders in hairdressers: A cross sectional study on the influence of working conditions and psychological, ergonomic and physical factors
- Author
-
L. De Smet, Filip Germeys, and E De Smet
- Subjects
Adult ,Male ,Engineering ,medicine.medical_specialty ,Adolescent ,Cross-sectional study ,Burnout ,Work related ,Beauty Culture ,Upper Extremity ,Young Adult ,Belgium ,Occupational Exposure ,medicine ,Humans ,Musculoskeletal Diseases ,Workplace ,Aged ,business.industry ,Hand size ,Rehabilitation ,Public Health, Environmental and Occupational Health ,Human factors and ergonomics ,Middle Aged ,Cross-Sectional Studies ,medicine.anatomical_structure ,Physical therapy ,Upper limb ,Female ,Ergonomics ,General health ,business - Abstract
A cross sectional study where 145 hairdressers were interviewed for the occurrence of work related upper limb disorders (WRULD). The interview features for engagement, burnout and workaholism, as well as asks for general health and working conditions. The BMI, the hand size and gripping force of each worker was obtained. WRULD was present in 41%. It was significantly correlated with burnout and workaholism. Surprisingly it was not altered by engagement or by the use of ergonomic equipment. Morphological features (BMI), hand size and gripping force, were not related to the occurrence of WRULD.
- Published
- 2009
37. The feasibility and safety of routine thrombus aspiration in patients with non-ST-elevation myocardial infarction
- Author
-
Ad F. M. van den Heuvel, Tone Svilaas, Rutger L. Anthonio, Facc Felix Zijlstra Md, Bart J. G. L. de Smet, Gillian A.J. Jessurun, Mathijs Vogelzang, Gilles F. H. Diercks, Eng-Shiong Tan, Albert J. H. Suurmeijer, Pieter J. Vlaar, Guided Treatment in Optimal Selected Cancer Patients (GUTS), and Translational Immunology Groningen (TRIGR)
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Embolism ,Myocardial Infarction ,PERCUTANEOUS CORONARY INTERVENTION ,PRIMARY ANGIOPLASTY ,Suction ,Coronary Angiography ,Balloon ,Risk Assessment ,acute coronary syndrome (ACS) ,Internal medicine ,Angioplasty ,medicine ,Humans ,REPERFUSION ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,cardiovascular diseases ,Embolization ,Myocardial infarction ,Angioplasty, Balloon, Coronary ,Prospective cohort study ,Aged ,Thrombectomy ,business.industry ,Coronary Thrombosis ,Incidence (epidemiology) ,Percutaneous coronary intervention ,General Medicine ,Middle Aged ,EMBOLIZATION ,medicine.disease ,Treatment Outcome ,Conventional PCI ,cardiovascular system ,Cardiology ,Feasibility Studies ,REMEDIA TRIAL ,Female ,embolization (EMBO) ,percutaneous coronary intervention (PCI) ,Cardiology and Cardiovascular Medicine ,business - Abstract
Objectives: To investigate the feasibility and safety of manual thrombus aspiration in patients undergoing percutaneous coronary intervention (PCI) for non-ST-elevation myocardial infarction (NSTEMI). Background: Myocardial necrosis in patients with acute coronary syndromes may be a sign of microvascular obstruction, owing to spontaneous or PCI-induced embolization of atherothrombotic material. Manual thrombus aspiration results in improved myocardial reperfusion in patients undergoing PCI for ST-elevation myocardial infarction. Currently, no published data on thrombus aspiration in patients with NSTEMI are available. Methods: As part of a prospective cohort study, 70 patients undergoing PCI for NSTEMI were treated with thrombus aspiration (Export Aspiration Catheter, Medtronic, Minneapolis, MN). Histopathological analysis was performed on aspirated material. Results: Thrombus aspiration was effective in 58 patients (83%) and resulted in a marked reduction of TIMI-thrombus score 4/5 (40% pre-versus 7% postthrombus aspiration) and increase of the rate of TIMI-flow 3 (36% pre-versus 66% postthrombus aspiration). The incidence of myocardial blush grade 2 and 3 were 39 and 45%, respectively. Distal embolization was visible in three patients (4%) on the final angiogram. Conclusion: This study demonstrates that thrombus aspiration in most NSTEMI patients is feasible and safe and is associated with a high rate of retrieval of thrombotic material. (C) 2008 Wiley-Liss, Inc.
- Published
- 2008
38. Computed tomographic angiography or conventional coronary angiography in therapeutic decision-making
- Author
-
Matthijs Oudkerk, Tineke P. Willems, Lieuwe H. Piers, Riksta Dikkers, Bart J. G. L. de Smet, Felix Zijlstra, René A. Tio, Vascular Ageing Programme (VAP), and Cardiovascular Centre (CVC)
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Decision Making ,Coronary Artery Disease ,Coronary Angiography ,Revascularization ,GUIDELINES ,Sensitivity and Specificity ,Coronary artery disease ,Coronary artery bypass surgery ,Germany ,Positive predicative value ,Image Processing, Computer-Assisted ,medicine ,Humans ,ARTERY-DISEASE ,DIAGNOSTIC-ACCURACY ,Aged ,CARDIOLOGY ,medicine.diagnostic_test ,business.industry ,Coronary Stenosis ,Percutaneous coronary intervention ,Middle Aged ,medicine.disease ,Stenosis ,medicine.anatomical_structure ,Angiography ,Female ,Radiology ,Tomography, X-Ray Computed ,Cardiology and Cardiovascular Medicine ,business ,Artery ,TASK-FORCE ,INTERVENTIONS - Abstract
Aims To evaluate non-invasive angiography using dual-source computed tomography (CT) for the determination of the most appropriate therapeutic strategy in patients with suspected coronary artery disease (CAD). Methods and results CT angiography (Dual Source CT, Somatom Definition, Siemens Medical Systems, Forchheim, Germany) was performed in 60 consecutive patients [51 men, median age 64 (57–70) years] scheduled for elective coronary angiography. Both techniques were used to evaluate the presence of CAD, significant stenosis, and the need for revascularization therapy. Sensitivity and specificity for the presence of significant stenosis were: per segment ( n = 766) 62% (95% CI 50–72) (64/104) and 79% (95% CI 74–84) (526/662), respectively; per patient ( n = 60) 100% (95% CI 91–100) (38/38) and 45% (95% CI 24–68) (10/22), respectively. In therapeutic decision-making based on CT angiography, sensitivity, specificity, positive and negative predictive values for intervention were 97% (95% CI 84–100) (36/37), 48% (95% CI 27–69) (11/23), 75% (95% CI 60–86) (36/48), and 92% (95% CI 60–100) (11/12), respectively. If a revascularization procedure was needed, the CT angiographic data indicated the appropriate modality (percutaneous coronary intervention or coronary artery bypass grafting) in 70% (26/36) of patients. Conclusion Although imaging qualities have improved considerably, CT angiography cannot be used for definitive therapeutic decision-making with regard to revascularization procedures in patients with suspected CAD.
- Published
- 2008
39. Measurement of the236U(n,f) Cross Section in the Neutron Energy Range from 0.5 eV up to 25 keV
- Author
-
O Serot, S. Vermote, J. Heyse, C. Wagemans, J Van Gils, and L. De Smet
- Subjects
Physics ,Range (particle radiation) ,010308 nuclear & particles physics ,Astrophysics::High Energy Astrophysical Phenomena ,0211 other engineering and technologies ,02 engineering and technology ,01 natural sciences ,Neutron temperature ,Nuclear physics ,Cross section (physics) ,Electron linear accelerator ,Nuclear Energy and Engineering ,0103 physical sciences ,Uranium-235 ,Physics::Accelerator Physics ,Neutron ,021108 energy - Abstract
The 236U(n,f) cross section has been measured in the energy range from 0.5 eV to 25 keV at the Geel Electron Linear Accelerator neutron time-of-flight facility of the Institute for Reference Materi...
- Published
- 2008
40. Rescue of arterial function by angiotensin-(1-7): towards improvement of endothelial function by drug-eluting stents
- Author
-
E. Tijsma, B. E. Langeveld, Freek J. Zijlstra, B. J. G. L. de Smet, W. H. Van Gilst, Arnold J. M. Driessen, A. J. M. Roks, Robert H. Henning, Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), Vascular Ageing Programme (VAP), Groningen Institute for Organ Transplantation (GIOT), Anesthesiology, and Internal Medicine
- Subjects
Drug ,Neointima ,medicine.medical_specialty ,endothelium ,Endothelium ,media_common.quotation_subject ,medicine.medical_treatment ,RATS ,prostaglandins ,Restenosis ,nitric oxide ,Internal medicine ,Renin–angiotensin system ,angiotensin-(1-7) ,Medicine ,cardiovascular diseases ,media_common ,endothelium-dependent hyperpolarisation factor ,business.industry ,Stent ,equipment and supplies ,medicine.disease ,DYSFUNCTION ,surgical procedures, operative ,medicine.anatomical_structure ,Dilator ,Heart failure ,cardiovascular system ,Cardiology ,HEART-FAILURE ,Original Article ,stent ,IMPLANTATION ,RESTENOSIS ,Cardiology and Cardiovascular Medicine ,business ,INTERVENTION - Abstract
Purpose: To explore the hypothesis that stent placement decreases dilator function of various arteries outside the stented segment and that angiotensin(1-7) improves this function, and to assess the contribution of dilator signal compounds. A further objective was to test the hypothesis that on-stent delivery of Ang-(1-7) reduces neointima formation and improves endothelial function. Methods. Abdominal aortic stenting or sham operation was performed in the rat four weeks after stenting and treatment with intravenous saline or Ang-(1-7) infusion (24 ug/kg/h); vasomotor function in isolated thoracic aorta and brachial and iliac artery was measured in organ baths. Furthermore, Ang-(1-7)-eluting stents were designed and placed in rat abdominal aorta. Neointima formation and aortic function were tested after four weeks. Results: Relaxation of the thoracic aorta to metacholine was decreased after stenting compared with shams due to a decrease in nitric oxide-mediated response (67% reduction in maximal NO-dependent response). Ang-(1-7)restored the response mainly through increased prostaglandin- and possibly also endothelial-derived hyperpolarising factor-mediated relaxation. Relaxation in the brachial artery decreased after stenting (maximal response dropped by 50%), whilst contractions to phenylephrine increased. Ang-(1-7) normalised vasomotor function. Iliac artery function remained unaltered after stenting but Ang-(1-7) increased maximal relaxations by 65%. Delivery of Ang-(1-7) by means of a drug-eluting stent improved endothelial function. Conclusion: Stenting differentially affects dilator and contractile function in various arterial beds. Ang-(1-7) both improves dilator function and normalises contractile function. Delivery of protective peptides such as Ang-(1-7) from the stent is a new therapy option that merits further development and exploration.
- Published
- 2008
41. A Comparison of 2 Thrombus Aspiration Devices With Histopathological Analysis of Retrieved Material in Patients Presenting With ST-Segment Elevation Myocardial Infarction
- Author
-
Rutger L. Anthonio, Felix Zijlstra, Gillian A.J. Jessurun, Ad F. M. van den Heuvel, Bart J. G. L. de Smet, Albert J. H. Suurmeijer, Tone Svilaas, Esjong Tan, Pieter J. Vlaar, Mathijs Vogelzang, Gilles F. H. Diercks, Guided Treatment in Optimal Selected Cancer Patients (GUTS), and Translational Immunology Groningen (TRIGR)
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Percutaneous coronary intervention ,medicine.disease ,Surgery ,Catheter ,Coronary thrombosis ,Embolism ,Internal medicine ,Angioplasty ,medicine ,Cardiology ,cardiovascular diseases ,Myocardial infarction ,business ,Cardiology and Cardiovascular Medicine ,TIMI ,Cardiac catheterization - Abstract
Objectives The objective of this study was to compare 2 manual thrombus aspiration catheters in unselected patients with ST-segment elevation myocardial infarction.Background Distal embolization is common during percutaneous coronary intervention in ST-segment elevation myocardial infarction and can induce impaired myocardial perfusion. Several aspiration thrombectomy devices have been introduced to prevent distal embolization, however, with conflicting clinical results. Currently, it is unclear to what extent this variance in outcome can be explained by device-related factors, such as internal lumen size.Methods We performed a prospective cohort study in which patients undergoing primary percutaneous coronary intervention were treated with a large-internal-lumen catheter (Diver, Invatec, Roncadelle, Italy). Outcomes were compared with a matched population of the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS) trial, in which patients were treated with a medium-sized catheter (Export, Medtronic, Minneapolis, Minnesota). A histopathological analysis was performed of retrieved material.Results A total of 160 patients, treated with the Diver (n = 80) or Export (n = 80) aspiration catheter, were enrolled. Effective thrombus aspiration was seen in 70.3% of the patients treated with the Diver catheter versus 81.8% with the Export catheter (p = 0.10) No significant difference was found in myocardial blush grade or electrocardiographic outcome between the 2 devices. Size distribution of retrieved thrombotic particles was similar per device. Erythrocyte-rich thrombi were found in 34.8% of the cases and were predominately seen in patients with low initial Thrombolysis In Myocardial Infarction flow grade (p = 0.008).Conclusions A larger internal lumen diameter does not result in retrieval of larger thrombotic particles, nor in improved angiographic or electrocardiographic outcomes. (J Am Coll Cardiol Intv 2008; 1:258-64) (C) 2008 by the American College of Cardiology Foundation
- Published
- 2008
- Full Text
- View/download PDF
42. Factors influencing return to work after surgical treatment for carpal tunnel syndrome
- Author
-
R. De Kesel, Peter Donceel, and L. De Smet
- Subjects
Adult ,Male ,medicine.medical_specialty ,Time Factors ,Multivariate analysis ,Occupational medicine ,Disability Evaluation ,Young Adult ,medicine ,Humans ,Carpal tunnel ,Occupations ,Young adult ,Carpal tunnel syndrome ,Retrospective Studies ,business.industry ,Public Health, Environmental and Occupational Health ,Retrospective cohort study ,Middle Aged ,Decompression, Surgical ,medicine.disease ,Carpal Tunnel Syndrome ,Occupational Diseases ,Treatment Outcome ,medicine.anatomical_structure ,Multivariate Analysis ,Sick leave ,Physical therapy ,Female ,Sick Leave ,business ,Psychosocial - Abstract
Background Controversy exists regarding the factors influencing the duration of work incapacity after surgically treated carpal tunnel syndrome (CTS). Aim To determine relevant factors related to return to work. Methods Surgical technique, clinical factors, demographic factors, other medical problems, psychosocial factors, work-related and economical factors were reviewed in patients operated on for CTS. Statistical multivariate analyses were performed to identify the baseline factors influencing the work incapacity period. Results A total of 107 cases were reviewed. Professional exposure to repetitive movements and heavy manual handling activity were associated with a longer return-to-work interval. The duration of work incapacity period was not significantly related to the socioprofessional category of the patient (self-employed or employee) or to the type of the procedure (open versus endoscopic surgery). Conclusion Work-related features have a more important influence on return to work than personal, pathological or surgical features.
- Published
- 2008
43. Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat
- Author
-
Pim van der Harst, Wiek H. van Gilst, Felix Zijlstra, Anton J.M. Roks, Hendrik Buikema, Bart J. G. L. de Smet, Hendrik C. Groenewegen, Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), and Vascular Ageing Programme (VAP)
- Subjects
Male ,Neointima ,medicine.medical_specialty ,CORONARY-ARTERY ,ENDOTHELIAL FUNCTION ,angiotensin II ,Pharmacology ,THERAPY ,SIROLIMUS-ELUTING STENT ,Random Allocation ,restenosis ,Restenosis ,Internal medicine ,medicine.artery ,medicine ,Animals ,Thoracic aorta ,Rosuvastatin ,cardiovascular diseases ,Rats, Wistar ,Rosuvastatin Calcium ,MUSCLE-CELL-PROLIFERATION ,Sulfonamides ,Hyperplasia ,business.industry ,Muscle cell proliferation ,Graft Occlusion, Vascular ,SMOOTH-MUSCLE ,General Medicine ,medicine.disease ,Angiotensin II ,CHRONIC HEART-FAILURE ,Rats ,Fluorobenzenes ,MODEL ,hydroxymethylglutaryl coenzyme-reductase inhibitors ,Pyrimidines ,PROGENITOR CELLS ,stents ,Dilator ,cardiovascular system ,Cardiology ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Tunica Intima ,Cardiology and Cardiovascular Medicine ,business ,rosuvastatin ,medicine.drug - Abstract
We investigated the efficacy of oral rosuvastatin treatment to reduce in-stent neointima formation, both in the absence and presence of high levels of the proproliferative substance angiotensin II (Ang II).Drawbacks of current drug-eluting stents include inhibition of reendothelialization, induction of abnormal coronary endothelial function, and, most importantly, late in-stent thrombosis. Statin treatment might be a more subtle approach, with known beneficial vascular effects.Wistar rats were allocated to four treatment groups by two consecutive randomization steps: one to allocate rosuvastatin 0.047% (wt/wt) supplemented rat chow, and one to implant an osmotic minipump releasing Ang II (200 ng/kg). Stents were implanted in the abdominal aorta in all groups. After 4 weeks, in-stent neointima formation and vascular function in the thoracic aorta were determined.In the absence of Ang II, rosuvastatin reduced neointima formation by 23% as compared with control (0.66+/-0.06 versus 0.51+/-0.02 mm2; P0.05). The presence of Ang II enhanced neointimal area by 30%. This was inhibited to the same extent by rosuvastatin (0.88+/-0.06 versus 0.67+/-0.03 mm2; P0.05). In parallel, rosuvastatin improved endothelial-dependent vasodilatation, both in the presence and absence of high levels of Ang II.Ang II infusion increases in-stent neointima formation and decreases endothelial function. We now provide evidence that rosuvastatin effectively inhibits in-stent neointima formation and in parallel improves endothelial dilator function, both in the presence and absence of high Ang II levels.
- Published
- 2008
44. Arthroscopie du poignet. Technique, aspects normaux
- Author
-
L. De Smet
- Subjects
business.industry ,Medicine ,business - Published
- 2008
45. Méthodes thérapeutiques : arthroscopie du poignet
- Author
-
L. De Smet
- Subjects
business.industry ,Medicine ,business - Published
- 2008
46. Contents Vol. 45, 2008
- Author
-
Yong-Xiao Wang, Shelly L. Stephens, Ayman Al Haj Zen, Kris Meurrens, John R. Barbour, Bart J. G. L. de Smet, Qing-Song Wang, Robert Pyo, Sylvia Colliec-Jouault, Enzo Porteri, Silvia Paiardi, Pedro Geraldes, Eric Durand, Enrico Agabiti-Rosei, Raymond Schleef, George Osol, Shenikqua Bouges, Marco Miclini, Gianni D Angelini, Stefan Lebrun, Jeffrey A. Jones, Yun-Min Zheng, Isabelle Cloutier, Anne-Marie Fischer, Haiyan Xu, Martin G. Sirois, Wiek H. van Gilst, Vishal R. Yadav, Céline Dujols, Piero Del Soldato, Jonathan Katz, Igor Chereshnev, Gianluca E.M. Boari, Francis G. Spinale, Mark B. Taubman, Nicola Rizzardi, Qing-Hua Liu, Marco R. Schroeter, Hendrik C. Groenewegen, Carolina De Ciuceis, Jamie Y. Jeremy, Tim Humboldt, Maaike Goris, An Berges, Geanina Onuta, Damiano Rizzoni, Barrett J. Rollins, Israel F. Charo, Thomas Wallerath, Saima Muzaffar, Jan Rozing, Jean-François Tanguay, Michael J. Mulvany, Patrick Bruneval, Felix Zijlstra, Pascale Geoffroy, Anton J.M. Roks, Dominique Helley, Robert E. Stroud, Mark Bond, Jan-Luuk Hillebrands, John S. Ikonomidis, Nilima Shukla, Rakesh Rathore, Anna Sparatore, Katrin Schaefer, Maren Leifheit, Guido A. M. Tiberio, Francesca Zani, Matthias Sawalich, Stavros Konstantinides, Caterina Platto, Andrew C. Newby, Antoine Lafont, Andre Zandvoort, Stefano Maria Giulini, and Jeffrey D. Alexis
- Subjects
Physiology ,Cardiology and Cardiovascular Medicine - Published
- 2008
47. Mycobacterium Marinum Infections of the Hand: a Report of Three Cases
- Author
-
L. De Smet
- Subjects
Male ,medicine.drug_class ,Antibiotics ,Mycobacterium Infections, Nontuberculous ,Microbiology ,Tendons ,Leisure Activities ,Synovitis ,Mycobacterium marinum Infection ,Humans ,Medicine ,Mycobacterium marinum ,biology ,business.industry ,Soft Tissue Infections ,Hypertrophy ,General Medicine ,Middle Aged ,Hand ,biology.organism_classification ,medicine.disease ,Contaminated water ,Fresh water ,Immunology ,Female ,Surgery ,Tomography, X-Ray Computed ,business ,Prolonged treatment ,Mycobacterium - Abstract
We report three cases of mycobacterium marinum infection, characterized by the long duration before a proper diagnosis was made. Mycobacterium marinum is a so-called atypical non-tuberculous mycobacterium, found in salt and fresh water, occasionally infecting humans. Most of the infections involve the fingers and hand, after exposure to contaminated water. It is commonly called fish tank infection. The clinical pictures can be very different: from a small cutaneous lesion to deep-seated infections of the tendon sheet or joint. Special transport and culture techniques are required for proper diagnosis. Besides surgical treatment of chronic skin lesions and deep infections, prolonged treatment with appropriate antibiotics is required.
- Published
- 2008
48. Chronic elbow dislocation: a rare complication of tennis elbow surgery. Successful treatment by open reduction and external articular distrator
- Author
-
L. De Smet and Ilse Degreef
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Elbow ,Radial tunnel syndrome ,General Medicine ,musculoskeletal system ,medicine.disease ,Surgery ,Posterior interosseous nerve ,medicine.anatomical_structure ,Elbow dislocation ,Orthopedic surgery ,medicine ,Tennis elbow ,Orthopedics and Sports Medicine ,Joint dislocation ,business ,Reduction (orthopedic surgery) - Abstract
A case is presented of chronic dislocation of the elbow after tennis elbow surgery combined with posterior interosseous nerve (PIN) release. An open reduction with repair of the collateral ligaments was performed. Postoperative rehabilitation involved the use of an articulated external fixator and there was a successful outcome. Possible causes of the dislocation are discussed.
- Published
- 2007
49. High Resolution Measurement of the 234U(n,f) Cross Section in the Neutron Energy Range from 0.5 eV to 100 keV
- Author
-
Jan Wagemans, O Serot, Cyrillus Wagemans, J. Heyse, L. De Smet, and J Van Gils
- Subjects
Physics ,Range (particle radiation) ,010308 nuclear & particles physics ,Fission ,0211 other engineering and technologies ,02 engineering and technology ,01 natural sciences ,Resonance (particle physics) ,Neutron temperature ,Nuclear physics ,Cross section (physics) ,Nuclear Energy and Engineering ,0103 physical sciences ,Uranium-235 ,Neutron source ,Neutron ,021108 energy ,Atomic physics - Abstract
The 234 U(n,f) cross section has been measured in the energy range from 0.5 eV to 100 keV at the GELINA neutron time-of-flight facility of the Institute for Reference Materials and Measurements in Geel using highly enriched 234 U samples. Two independent measurements were performed: one in a low detection geometry (15% of 2π) and another in a 2π detection geometry. A 235 U(n,f) cross-section measurement was performed under the same experimental conditions, allowing a reliable correction for the 235 U(n,f) contribution to the yield. Special attention has been given to the strongest resonance at 5.16 eV and to the fission resonance integral I f , for which large discrepancies are reported in the literature.
- Published
- 2007
50. Giant cell tumor of distal phalanx in an adolescent with Goltz-Gorlin syndrome
- Author
-
A, Borgers, S, Peters, R, Sciot, and L, De Smet
- Subjects
Focal Dermal Hypoplasia ,Adolescent ,Thumb ,Giant Cell Tumors ,Humans ,Bone Neoplasms ,Female - Abstract
We report on a unique case of a young female patient with the Goltz-Gorlin syndrome who developed a giant cell tumor of bone in the distal phalanx of the thumb. This case is noteworthy because of the combination of some unusual features. Firstly, it is only the fifth case report on the association of giant cell tumor of bone and the Goltz-Gorlin syndrome. Also the localization of the lesion in the bones of the hand and the presentation at adolescent age is rarely seen.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.